interleukin

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

Reslizumab (Sch 55700) is a humanized immunoglobulin G (IgG)4 κ monoclonal antibody that binds to human interleukin 5, thereby decreasing eosinophil production and survival.Reslizumab improves lung function, induces a decrease in eosinophil production and maturation, and may be used in the study of asthma.

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.

Basiliximab (CHI 621) is a chimeric mouse/human IgG1 monoclonal recombinant antibody targeting the interleukin-2 receptor, demonstrating potent immunosuppressive activity for use in kidney transplantation studies.

Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under research for treating psoriatic arthritis (PsA) and renal antibody-mediated rejection [1] [2].

Lebrikizumab is a humanised monoclonal antibody that targets and inhibits interleukin 13 (IL-13), thereby suppressing Th2 inflammation. It is mainly used in the study of asthma and atopic dermatitis.

Satralizumab (SA-237) is a humanized monoclonal antibody targeting interleukin-6 (IL-6), acting in neuromyelitis optica spectrum disorder (NMOSD). It is used in studies of neuromyelitis optica.

Nemolizumab (CIM331) is a humanized monoclonal antibody targeting the human interleukin-31 receptor A, inhibiting IL-31 binding and subsequent signal transduction. It is useful for studying atopic dermatitis with pruritus.

Enokizumab (MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.

Fletikumab (NNC0109-0012) is a monoclonal antibody that inhibits IL-20, primarily used in research on rheumatoid arthritis and psoriasis.

Pivekimab is a high-affinity humanised monoclonal antibody targeting CD123 (IL-3RA), which can be used to synthesise the ADC molecule pivekimab sunirine, for the study of acute myeloid leukaemia and blast plasmacytoid dendritic cell neoplasm (BPDCN).

Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.

Bermekimab (MABp1) is a humanized monoclonal antibody against interleukin-1α (IL-1α).Bermekimab has potential anti-inflammatory activity to prevent skin inflammation.

Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.

Elsilimomab (B-E8) is a monoclonal antibody targeting interleukin-6 (IL-6), inhibiting DNMT3A mutant clone-induced hematopoietic stromal cell senescence, used in the study of multiple myeloma and renal cell carcinoma.

Sirukumab (CNTO-136) is a selective humanized monoclonal antibody binding to Interleukin-6 (IL-6), inhibiting IL-6-mediated signal transduction and activation of transcription factors. It is used in lupus nephritis and rheumatoid arthritis research.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affinity for CD123, CD32b/c, CD16-158F and CD16-158V, with KD of 0.43 nM, 188 nM, 46 nM and 16.8 nM, respectively. Talacotuzumab inhibits IL-3 signaling in target cells by inhibiting IL-3 binding to CD123. Talacotuzumab induces mutations in the Fc region to increase affinity for CD16 (FCγriiia), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab inhibits leukemia cell growth in xenografted mouse models of acute myeloid leukemia (AML).

Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways. Spesolimab can be used to study systemic pustular psoriasis, palmar and plantar impetigo (PPP), and atopic dermatitis.

Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody combining monovalent camelid-derived nanobodies targeting human interleukin (IL)-17A and IL-17F with human serum albumin VHHs, presenting it as a promising candidate for investigating plaque-type psoriasis treatments [1] [2].

Oxelumab (R 4930) is a human monoclonal antibody targeting OX40L, and could be used to study asthma.